dyspepsia/acidente vascular cerebral

O link é salvo na área de transferência

Escolha o tipo de classificação

Página 1 a partir de 81 resultados

[Elongated needle for post-stroke indigestion].

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE To observe the clinical efficacy difference among elongated needle, filiform needle and medication for post-stroke indigestion. METHODS Sixty cases of post-stroke indigestion were randomly assigned into an elongated needle group, a filiform needle group and a medication group, 20 cases in

I had a mild stroke two years ago, but recovered completely and am now healthy and active. After my stroke, my doctor prescribed a statin medication, even though I don't have heart disease. The medication gives me indigestion. Can I stop it without any problems?

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND Low-dose aspirin (ASA) is effective for secondary prevention of ischemic stroke but can increase the risks of hemorrhagic stroke, upper gastrointestinal bleeding (UGIB), and dyspepsia. Prophylactic administration of proton pump inhibitors (PPIs) reduces the risks of these digestive

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND There are growing concerns for the side effects of dabigatran etexilate (dabigatran), including higher incidence of dyspepsia and gastrointestinal bleeding. We conducted a multicenter early implementation study to prospectively evaluate the safety, efficacy and adherence to dabigatran for

Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND Warfarin is the only oral anticoagulant recommended for the prevention of ischemic stroke in atrial fibrillation. A newer and safer anticoagulant is needed because of increased hemorrhagic risks with warfarin, difficult-to-maintain therapeutic levels, and higher drug to drug and food

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China. METHODS Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively

A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

The use of novel anticoagulants such as dabigatran are increasing. Despite increased risks of intracerebral haemorrhage with warfarin among Asians, there is little published data on dabigatran to assess 'real world' efficacy and safety of dabigatran therapy in Asia. This was a retrospective

Spotlight on dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

The need for safe, effective and easily administered and monitored antithrombotic treatments that do not have the issues common to warfarin treatment has led to the development of new anticoagulant drugs. Dabigatran etexilate (Pradaxa®, Pradax™) is a prodrug of the direct thrombin inhibitor

Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

The need for safe, effective, and easily administered and monitored antithrombotic treatments that do not have the issues common to warfarin treatment has led to the development of new anticoagulant drugs. Dabigatran etexilate (Pradaxa®, Pradax™) is a prodrug of the direct thrombin inhibitor

Dyspepsia and disease burden among patients with atrial fibrillation.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

This retrospective, observational study was conducted to determine overlap of prevalence between atrial fibrillation (AF), an increasingly common condition that primarily affects the elderly population, and dyspepsia, which is also common. Because the overlap of these conditions could interfere with

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

This article provides an overview of the clinical profile of oral dabigatran etexilate (Pradaxa®, Pradax™) [hereafter referred to as dabigatran] when used for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), followed by a review of cost-utility

Health care burden of dyspepsia among nonvalvular atrial fibrillation patients.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND Although dyspepsia is common among nonvalvular atrial fibrillation (NVAF) patients, its impact on patient health and cost has not been adequately studied. OBJECTIVE To evaluate the incremental health care burden associated with dyspepsia among NVAF patients and its impact on warfarin

[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of

Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of dabigatran are freedom from monitoring and less interaction with other drugs and food. It is ideal for patients who

Candida esophagitis with fever alone in a patient with stroke.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND Candida esophagitis is a rare disease, but its incidence is higher in patients with impaired immunity due to an underlying disease. Patients with candida esophagitis usually present with lower retrosternal pain or dysphagia, but they are sometimes asymptomatic. Several risk factors,

Junte-se à nossa
página do facebook

Herbal & Natural Medicine

O mais completo banco de dados de ervas medicinais apoiado pela ciência

Funciona em 55 idiomas
Curas herbais apoiadas pela ciência
Reconhecimento de ervas por imagem
Mapa GPS interativo - marcar ervas no local (em breve)
Leia publicações científicas relacionadas à sua pesquisa
Pesquise ervas medicinais por seus efeitos
Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas